Lv4
498 积分 2024-10-11 加入
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
19天前
已完结
First CAR T-Cell Therapy Approved for Solid Tumors
19天前
已关闭
The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer
19天前
已完结
Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer
19天前
已完结
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
19天前
已完结
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
21天前
已完结
Engineered Treg cells: The heir to the throne of immunotherapy
24天前
已完结
Chimeric antigen receptor Treg therapy in transplantation
24天前
已完结
Abstract 128: Synthetic reprogramming of γδ CAR T cells with the LTBR gene optimizes function in the TME and overcomes effector limitations
1个月前
已关闭
The emerging roles of γδ T cells in cancer immunotherapy
1个月前
已完结
皖公网安备34019202002308
